Here's Why You Should Retain PODD Stock in Your Portfolio Now

Key Takeaways PODD is seeing strong growth from its Omnipod 5 system, especially among Type 2 diabetes patients. Insulet expanded Omnipod 5 into 11 new international markets in early 2025. Macroeconomic headwinds and rising competition pose risks to PODD's growth and pricing power.Insulet Corporation’s (PODD) rapid commercial expansion of its Omnipod platform is poised to help it grow in the upcoming quarters. The rising adoption of Omnipod 5 also presents a promising growth opportunity. Meanwhile, advers ...